Pomalyst 3 MG
Ended Awarded Last action
- Contract number
- 36C24526N0431
- Awardee
-
Bristol-Myers Squibb Company UEI UFGKB2B71N12
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $10,888
Award facts
- Contract value 100% obligated
- $10,887.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Memphis, TN 38141, USA
Award details come from SAM.gov/FPDS.
About this award
Bristol-Myers Squibb Company, a global biopharmaceutical manufacturer headquartered in Lawrenceville, New Jersey, has been awarded a delivery order for POMALYST 3 MG by Veterans Integrated Service Network 5 (VISN 5), a civilian component of the Department of Veterans Affairs. This Blanket Purchase Agreement (BPA) call, issued on March 20, 2026, carries a ceiling value of $10,887.52 and is structured as a firm fixed-price contract with an ultimate completion date of March 27, 2026. The award represents a delivery order issued under Bristol-Myers Squibb's existing Federal Supply Schedule contract (ID: 36F79724D0101) for Pharmaceuticals and Drugs (FSS-61-IB), which holds a substantial ceiling value of $12.3 billion and extends through April 30, 2029. The contract contains no set-aside designations, reflecting Bristol-Myers Squibb's status as a large pharmaceutical manufacturer.
POMALYST (pomalidomide) is a specialty oncology pharmaceutical used in the treatment of multiple myeloma and other hematologic malignancies, representing one of several advanced cancer therapies that Bristol-Myers Squibb supplies to the VA healthcare system. This delivery order will be performed in Memphis, Tennessee, and supports the Veterans Health Administration's broader mission to provide eligible veterans with access to current standard-of-care oncology and immunotherapy treatments. Bristol-Myers Squibb has demonstrated sustained engagement with the VA system, having received more than fifty documented delivery orders since 2022 across multiple Veterans Integrated Service Networks, underscoring consistent demand for the company's specialized pharmaceutical products within the federal healthcare system.
Quick answers
Who was awarded contract 36C24526N0431?
36C24526N0431 was awarded to Bristol-Myers Squibb Company by Veterans Integrated Service Network 5 (Veterans Health Administration) on March 20, 2026.
How much is contract 36C24526N0431 worth?
The government has obligated $10,888 on 36C24526N0431.
Is contract 36C24526N0431 an order under another contract?
Yes. 36C24526N0431 is a BPA call under 36F79724D0101-36E79726A0010, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0431 competed?
The extent of competition for 36C24526N0431 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award